1061743-02-9

Basic information

• Product Name: (R)-tert-butyl 8-(4'-methoxybiphenyl-4-ylsulfonyl)-10-methyl-3-oxo-1-phenyl-2,9-dioxa-4,8-diazaundecane-7-carboxylate
• Synonyms: (R)-tert-butyl 8-(4'-methoxybiphenyl-4-ylsulfonyl)-10-methyl-3-oxo-1-phenyl-2,9-dioxa-4,8-diazaundecane-7-carboxylate
• CAS NO: 1061743-02-9
• Molecular Weight: 612.744
• Mol File: 1061743-02-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R)-tert-butyl 8-(4'-methoxybiphenyl-4-ylsulfonyl)-10-methyl-3-oxo-1-phenyl-2,9-dioxa-4,8-diazaundecane-7-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl 8-(4'-methoxybiphenyl-4-ylsulfonyl)-10-methyl-3-oxo-1-phenyl-2,9-dioxa-4,8-diazaundecane-7-carboxylate(1061743-02-9)
• EPA Substance Registry System: (R)-tert-butyl 8-(4'-methoxybiphenyl-4-ylsulfonyl)-10-methyl-3-oxo-1-phenyl-2,9-dioxa-4,8-diazaundecane-7-carboxylate(1061743-02-9)

Safety Data

• Hazardous Substances Data: 1061743-02-9(Hazardous Substances Data)

Upstream product

• 849773-54-2 tert-butyl (2S)-4-{[(benzyloxy)carbonyl]amino}-2-hydroxybutanoate 
• 40371-50-4 S-4-benzyloxycarbonylamino-2-hydroxybutyric acid 
• 1061743-00-7 C₁₆H₁₉NO₄S 

Downstream Products

• 1061743-12-1 (R)-tert-butyl 2-(N-isopropoxy-4′-methoxybiphenyl-4-ylsulfonamido)-4-(2-phenylacetamido)butanoate 
• 1061743-13-2 (R)-2-(N-isopropoxy-4′-methoxybiphenyl-4-ylsulfonamido)-4-(2-phenylacetamido)butanoic acid 
• 1061742-53-7 (R)-N-hydroxy-2-(N-isopropoxy-4′-methoxybiphenyl-4-ylsulfonamido)-4-(2-phenylacetamido)butanamide 
• 1061746-23-3 C₃₄H₄₇N₃O₇SSi 

Relevant articles and documents

Diagnostic agents selective against metalloproteases

The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, G and n have the meanings reported in the specification, properly la

ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS

The invention relates to dimeric aryl-sulphonamido compounds endowed with inhibitory activity against metalloproteases MMP, having formula (I) below ???????? (M)-L-(M')?????(I) wherein M and M', the same or different from each other, represent the residues of the mctalloprotcascs inhibitors of formula (II) wherein R, R1, R2, R3, G and n have the meanings reported in the specification; the invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of degenerative disorders.